AR052643A1 - Memantina para el tratamiento de trastornos de conducta en la infancia - Google Patents
Memantina para el tratamiento de trastornos de conducta en la infanciaInfo
- Publication number
- AR052643A1 AR052643A1 ARP050103986A ARP050103986A AR052643A1 AR 052643 A1 AR052643 A1 AR 052643A1 AR P050103986 A ARP050103986 A AR P050103986A AR P050103986 A ARP050103986 A AR P050103986A AR 052643 A1 AR052643 A1 AR 052643A1
- Authority
- AR
- Argentina
- Prior art keywords
- memantine
- child
- treatment
- conduct disorders
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un método para el tratamiento de individuos con diagnostico de trastorno de conducta infantil, tal como los trastornos del espectro autista o la forma combinada del trastorno de déficit de atencion de hiperactividad (ADHD) mediante la administracion de una cantidad eficaz de memantina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61260004P | 2004-09-23 | 2004-09-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR052643A1 true AR052643A1 (es) | 2007-03-28 |
Family
ID=35445934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050103986A AR052643A1 (es) | 2004-09-23 | 2005-09-26 | Memantina para el tratamiento de trastornos de conducta en la infancia |
Country Status (16)
Country | Link |
---|---|
US (2) | US20060079582A1 (es) |
EP (1) | EP1799224A1 (es) |
JP (1) | JP2008514620A (es) |
KR (1) | KR20070046185A (es) |
CN (1) | CN101374525A (es) |
AR (1) | AR052643A1 (es) |
AU (1) | AU2005286672B2 (es) |
BR (1) | BRPI0515560A (es) |
CA (1) | CA2578953A1 (es) |
EA (1) | EA012036B1 (es) |
IL (1) | IL182105A0 (es) |
MX (1) | MX2007003267A (es) |
NO (1) | NO20072035L (es) |
TW (1) | TW200626160A (es) |
WO (1) | WO2006034465A1 (es) |
ZA (1) | ZA200702130B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7456224B2 (en) | 2004-04-05 | 2008-11-25 | Forest Laboratories Holdings, Ltd. | Method for treating autism |
EP2040676A2 (en) * | 2006-07-06 | 2009-04-01 | Forest Laboratories, Inc. | Orally dissolving formulations of memantine |
RU2326660C1 (ru) * | 2007-03-14 | 2008-06-20 | Закрытое акционерное общество "Биологические исследования и системы" | Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты) |
US20100292341A1 (en) * | 2007-06-29 | 2010-11-18 | Orchid Chemicals & Pharmaceuticals Limited | Quick dissolve compositions of memantine hydrochloride |
WO2009151498A2 (en) * | 2008-03-28 | 2009-12-17 | Forest Laboratories Holdings Limited | Memantine formulations |
EP2138173A1 (en) | 2008-06-26 | 2009-12-30 | Merz Pharma GmbH & Co.KGaA | Pharmaceutical compositions comprising aminoadamantane derivatives |
HUE032888T2 (hu) | 2008-12-08 | 2017-11-28 | Biocodex | Vegyületek és eljárások autizmus spektrum zavarok kezelésére |
IT1396556B1 (it) * | 2009-02-11 | 2012-12-14 | Serra | Uso di memantina per il trattamento di disturbi dell umore |
EP3034079B1 (en) | 2010-11-15 | 2018-01-10 | Agenebio, Inc. | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
RU2488388C1 (ru) * | 2012-05-24 | 2013-07-27 | Ооо "Валента Интеллект" | Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств |
WO2014015047A1 (en) | 2012-07-17 | 2014-01-23 | The General Hospital Corporation | Compositions and methods to treat neurodegenerative diseases |
UA107653U (uk) | 2012-10-01 | 2016-06-24 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів |
KR101424514B1 (ko) * | 2013-01-02 | 2014-07-31 | 건국대학교 산학협력단 | 선천성 발프로산 노출 증후군 치료제로서의 메만틴의 용도 |
EP3485882A1 (en) | 2013-01-25 | 2019-05-22 | Case Western Reserve University | Compositions for the treatment of pervasive development disorders |
WO2014153180A1 (en) * | 2013-03-14 | 2014-09-25 | Michela Gallagher | Methods and compositions for improving cognitive function |
CA2934553C (en) | 2013-12-20 | 2023-10-31 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
ES2909456T3 (es) * | 2015-05-22 | 2022-05-06 | Univ Arizona State | Métodos para tratar el trastorno del espectro autista y síntomas asociados |
MX2017015752A (es) | 2015-06-19 | 2018-04-13 | Agenebio Inc | Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo. |
KR20190040237A (ko) | 2016-08-24 | 2019-04-17 | 조게닉스 인터내셔널 리미티드 | 5-ht2b 작용물질의 형성을 억제하기 위한 제제 및 그것의 사용 방법 |
BR112019012821A2 (pt) | 2016-12-19 | 2019-11-26 | Agenebio Inc | derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo |
KR20200043401A (ko) * | 2017-08-01 | 2020-04-27 | 스튜어트 에이. 립튼 | 신경 질환을 치료하기 위한 방법 및 조성물 |
US20190091179A1 (en) * | 2017-09-26 | 2019-03-28 | Zogenix International Limited | Congnitive function with fenfluramine |
FR3075038B1 (fr) | 2017-12-15 | 2020-03-06 | Melchior Material And Life Science France | Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete |
MX2020013927A (es) | 2018-06-19 | 2021-03-02 | Agenebio Inc | Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo. |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH603545A5 (es) * | 1972-04-20 | 1978-08-31 | Merz & Co | |
HU169986B (es) * | 1972-12-07 | 1977-03-28 | ||
DE2856393C2 (de) * | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
US5366738A (en) * | 1982-07-29 | 1994-11-22 | Merck & Co., Inc. | Controlled release drug dispersion delivery device |
US6024983A (en) * | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
US4849222A (en) * | 1987-03-24 | 1989-07-18 | The Procter & Gamble Company | Mixtures for treating hypercholesterolemia |
JP2670680B2 (ja) * | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
ATE94384T1 (de) * | 1989-04-14 | 1993-10-15 | Merz & Co Gmbh & Co | Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie. |
US4994467A (en) * | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
US6057373A (en) * | 1997-05-22 | 2000-05-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists |
US6326226B1 (en) * | 1997-07-15 | 2001-12-04 | Lg. Philips Lcd Co., Ltd. | Method of crystallizing an amorphous film |
WO1999036064A2 (en) * | 1998-01-13 | 1999-07-22 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
US6362226B2 (en) * | 1999-12-08 | 2002-03-26 | Vanderbilt University | Modulation of in vivo glutamine and glycine levels in the treatment of autism |
US6727231B1 (en) * | 2000-10-12 | 2004-04-27 | Repligen Corporation | Uridine therapy for patients with elevated purine levels |
EP1471909A4 (en) * | 2002-01-16 | 2007-07-25 | Endo Pharmaceuticals Inc | PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM |
TW200410672A (en) * | 2002-07-19 | 2004-07-01 | Merz Pharma Gmbh & Co Kgaa | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau |
TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
-
2005
- 2005-09-23 KR KR1020077006537A patent/KR20070046185A/ko not_active Application Discontinuation
- 2005-09-23 MX MX2007003267A patent/MX2007003267A/es unknown
- 2005-09-23 CN CNA2005800321868A patent/CN101374525A/zh active Pending
- 2005-09-23 WO PCT/US2005/034199 patent/WO2006034465A1/en active Application Filing
- 2005-09-23 JP JP2007533663A patent/JP2008514620A/ja active Pending
- 2005-09-23 EA EA200700708A patent/EA012036B1/ru not_active IP Right Cessation
- 2005-09-23 AU AU2005286672A patent/AU2005286672B2/en not_active Ceased
- 2005-09-23 US US11/234,764 patent/US20060079582A1/en not_active Abandoned
- 2005-09-23 CA CA002578953A patent/CA2578953A1/en not_active Abandoned
- 2005-09-23 BR BRPI0515560-6A patent/BRPI0515560A/pt not_active IP Right Cessation
- 2005-09-23 EP EP05802627A patent/EP1799224A1/en not_active Withdrawn
- 2005-09-23 TW TW094133147A patent/TW200626160A/zh unknown
- 2005-09-26 AR ARP050103986A patent/AR052643A1/es not_active Application Discontinuation
-
2007
- 2007-03-13 ZA ZA200702130A patent/ZA200702130B/xx unknown
- 2007-03-21 IL IL182105A patent/IL182105A0/en unknown
- 2007-04-20 NO NO20072035A patent/NO20072035L/no not_active Application Discontinuation
-
2009
- 2009-10-30 US US12/609,105 patent/US20100081723A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1799224A1 (en) | 2007-06-27 |
WO2006034465A8 (en) | 2006-06-08 |
AU2005286672A1 (en) | 2006-03-30 |
US20060079582A1 (en) | 2006-04-13 |
CN101374525A (zh) | 2009-02-25 |
IL182105A0 (en) | 2007-07-24 |
JP2008514620A (ja) | 2008-05-08 |
MX2007003267A (es) | 2007-05-23 |
EA012036B1 (ru) | 2009-06-30 |
BRPI0515560A (pt) | 2008-07-29 |
KR20070046185A (ko) | 2007-05-02 |
AU2005286672B2 (en) | 2009-03-12 |
NO20072035L (no) | 2007-06-13 |
ZA200702130B (en) | 2008-09-25 |
EA200700708A1 (ru) | 2007-08-31 |
WO2006034465A1 (en) | 2006-03-30 |
US20100081723A1 (en) | 2010-04-01 |
CA2578953A1 (en) | 2006-03-30 |
TW200626160A (en) | 2006-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR052643A1 (es) | Memantina para el tratamiento de trastornos de conducta en la infancia | |
AR050623A1 (es) | Metodo para el tratamiento del trastorno de hiperactividad de deficit de atencion | |
UY31497A1 (es) | Nuevos compuestos para el tratamiento de trastornos del snc | |
BR112016029498A2 (pt) | canabidiol, método para tratamento de epilepsia, e, composição. | |
ECSP10010526A (es) | Compuesto heterociclico | |
BRPI0606542A2 (pt) | métodos para aumentar o tempo de progressão de uma doença (ttp) ou a sobrevivência, uso de um inibidor da dimerização de her e uso de pertuzumab | |
ECSP12012160A (es) | Compuesto heterociclico | |
CR20140223A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
UY33199A (es) | 5-alquinil-pirimidinas. | |
CO6321189A2 (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
CL2008002793A1 (es) | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras | |
BR112022003505A2 (pt) | Composições e métodos para tratamento de distúrbios associados a dna repetitivo | |
UY33017A (es) | Tratamiento para trastornos gastrointestinales | |
ECSP10010704A (es) | Sales y polimorfos de un compuesto de tetraticlina | |
ECSP10010730A (es) | Hidrogenación de alcanos multi-bromados | |
UY35518A (es) | Composicion de hidrocarburos renovable | |
ECSP11010786A (es) | 5-alquinil-pirimidinas | |
CL2012001031A1 (es) | Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros. | |
CL2014003429A1 (es) | Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia. | |
ECSP11010816A (es) | Nuevos Compuestos | |
CL2016001578A1 (es) | Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c. | |
BR112012014621B8 (pt) | Processo para a preparação de compostos de quelato | |
AR100734A1 (es) | Método para tratar leucemia linfocítica crónica (cll) | |
UY31700A (es) | Tiazolil-dihidro-indazoles | |
CL2009001018A1 (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia, teniendo los pacientes un incremento del nivel de creatinina debido a la utilizacion de dronedarona. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |